AstraZeneca's (AZN.US) BTK inhibitor approved for a new indication by the European Union for the treatment of mantle cell lymphoma

Zhijun Finance APP learned that on May 6th local time, AstraZeneca (AZN.US) announced that acalabrutinib in combination with bendamustine and rituximab has been approved in the European Union for the treatment of mantle cell lymphoma (MCL) in adult patients who have not received prior treatment and are not suitable for autologous stem cell transplantation. The press release pointed out that this is the first and only BTK inhibitor approved in the EU for this indication.